Sugi Predict

Sugi Predict / Compounds / SCHEMBL1145013

SCHEMBL1145013

SCHEMBL1145013

O=C(O)c1cc2cccc(F)c2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.60
▸ HSD17B10 Q99714 3/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ USP2 O75604 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ HRH4 Q9H3N8 6/20 0.58
▸ APEX1 P27695 2/20 0.58
▸ DAO P14920 2/20 0.56
▸ DDO Q99489 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ SRD5A2 P31213 1/20 0.53
▸ EIF4A3 P38919 1/20 0.53
▸ IDO1 P14902 1/20 0.51
▸ TDO2 P48775 1/20 0.51
▸ PDPK1 O15530 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ NFKB1 P19838 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27856030 0.87 HRH4 (0.60) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL29053576 0.85 HPGD (0.53) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL29053567 0.85 HSD17B10 (0.56) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL29053564 0.85 HPGD (0.53) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL30494485 0.85 HSD17B10 (0.56) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL30494448 0.85 HPGD (0.53) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL10084620 0.84 HRH4 (0.59) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL7942068 0.84 HRH4 (0.57) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL17136028 0.81 HSD17B10 (0.64) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL35212257 0.80 HRH4 (0.56) HRH4DAODDOCA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118562565-A Stable semiconductor chip cleaning liquid and preparation method and application thereof 浙江奥首材料科技有限公司 2024-08-30 — — CN claimed
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 — — US claimed
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 — — EP claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 — — EP claimed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 — — US claimed
EP-2094690-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-09-02 — — EP claimed
EP-2079690-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 — — EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO claimed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 — — WO claimed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 — — WO claimed
EP-4660193-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2025-12-10 — — EP disclosed
EP-4587433-A1 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS Takeda Pharmaceutical Company Limited (JP) 2025-07-23 — — EP disclosed
WO-2025101881-A1 HETEROATOM CONTAINING PEPTIDOMIMETICS TARGETING VIRAL PROTEASES EMORY UNIVERSITY (US) 2025-05-15 — — WO disclosed
EP-4536680-A1 RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF The Governors of the University of Alberta (CA) 2025-04-16 — — EP disclosed
EP-1671972-A1 Octahydropyrrolo[3,4-c]pyrrole derivatives Pfizer Limited (GB) 2006-06-21 — — EP disclosed
WO-2006056848-A1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES PFIZER LIMITED (GB) 2006-06-01 — — WO disclosed
US-20060111416-A1 Octahydropyrrolo[3,4-C]pyrrole derivatives PFIZER INC. 2006-05-25 — — US disclosed
CN-1265591-A Coumpound ZENECA LTD (GB) 2000-09-06 — — CN disclosed
US-5183820-A Useful for treatment of nausea, vomiting, irritable bowel syndrome and dyspepsia GLAXO GROUP LIMITED (GB) 1993-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111416-A1 Octahydropyrrolo[3,4-C]pyrrole derivatives DPYD, PAH, DHPS HPGD 70/4885HSD17B10 1676/4885ALDH1A1 275/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 HPGD 176/4885HSD17B10 297/4885ALDH1A1 834/4885
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 HPGD 1029/4885HSD17B10 1770/4885ALDH1A1 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.